SCHEMBL2400614

SCHEMBL2400614

Cc1nc2c(s1)C(=O)C(NCCCN(C)CCCNC1=CC(=O)c3nc(C)sc3C1=O)=CC2=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.62
CDC25B P30305 2/20 0.62
CDC25C P30307 2/20 0.62
S100A4 P26447 2/20 0.42
CDK4 P11802 9/20 0.41
BLM P54132 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
CCND1 P24385 1/20 0.41
KMT2A Q03164 1/20 0.41
KMT5A Q9NQR1 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
BRD4 O60885 2/20 0.36
ATAD2 Q6PL18 2/20 0.36
ALDH1A1 P00352 2/20 0.35
MALT1 Q9UDY8 1/20 0.35
APAF1 O14727 1/20 0.35
NPY5R Q15761 1/20 0.32
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2399947 0.92 CDC25A (0.68) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL2398380 0.90 CDC25A (0.77) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL2402571 0.88 CDC25A (0.73) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL2401281 0.86 CDC25A (0.75) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL2399099 0.84 CDC25A (0.69) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL2404140 0.83 CDC25A (0.66) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL1917822 0.82 CDC25A (0.85) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL3813511 0.82 CDC25A (0.77) CDC25ACDC25BCDC25CS100A4CDK4
SCHEMBL2404183 0.82 CDC25A (0.53) CDC25ACDC25BCDC25CCDK4BLM
SCHEMBL2401631 0.82 CDC25A (0.85) CDC25ACDC25BCDC25CS100A4CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed
EP-1831209-A2 CDC25 PHOSPHATASE INHIBITORS Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) 2007-09-12 EP disclosed
WO-2006067311-A2 CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.